# Evaluation of the gastrotolerability of ketoprofen, lysine, and gabapentin co-crystal administration in an in vitro model of gastric epithelium: a proteomic update

**Authors:** Francesco D’Egidio, Laura Brandolini, Vanessa Castelli, Massimiliano Quintiliani, Andrea Aramini, Annamaria Cimini, Marcello Allegretti, Michele d’Angelo, Anisha DSouza, Anisha DSouza, Anisha DSouza

PMC · DOI: 10.1371/journal.pone.0328496 · PLOS One · 2025-07-29

## TL;DR

This study evaluates how well a new drug combination of ketoprofen, lysine, and gabapentin is tolerated in the stomach using a lab model.

## Contribution

The study introduces a new ternary drug co-crystal and provides proteomic evidence of its improved gastric tolerability.

## Key findings

- The KLS-GABA co-crystal showed higher gastric tolerability compared to individual or combined drug administration.
- Proteomic analysis revealed modulation of oxidative stress-related proteins like GSTP1.
- 2DE and western blot confirmed differential proteomic changes in the gastric epithelium model.

## Abstract

Chronic pain is a distressful condition that impacts strongly on people’s health, and, to date, no cure has been found. However, several strategies against pain have been proposed. Promising data regarding the usage of nonsteroidal anti-inflammatory drugs (NSAIDs) in combination with gabapentin in pain management laid the foundations for more complex approaches. A recently published study proposed a multimodal approach based on ketoprofen lysine salt (KLS) combined with gabapentin (GABA) in the context of chronic pain. Experiments on in vitro models showed supra-additive effects in modulating key pathways involved in neuropathic pain and gastric mucosal damage. Thus, the co-crystallization of ketoprofen, lysine, and gabapentin led to a new ternary drug-drug co-crystal (KLS-GABA co-crystal) to better take advantage of such effects. The new compound showed positive features in in vitro and in vivo pain models, particularly at the gastrointestinal level. To better understand the gastric impact of the co-crystal we chose to analyze proteomic fluctuations that occur in an in vitro model of gastric epithelium upon ethanol injury, aiming to observe the gastric effects of KLS-GABA co-crystal’s administration in comparison with KLS or GABA alone or co-administered as in the multimodal approach. Thus, we performed a 2-dimensional gel electrophoresis (2DE) to compare proteomes from lysates of NCI-N87 cells, chosen as model of gastric epithelium. Among all the localized spots (n = 117), the differentially abundant ones have been filtered and excised (n = 24) to perform mass spectrometry. A total of 414 non-redundant proteins have been found in the excised spots analyzed. A Gene Ontology-based enrichment analysis identified the proteins involved in biological processes, cellular components, and pathways. We then compared the 2DE findings with the western blot analysis confirming the differential proteomic fluctuations in the model. The methodology described here provides a broader picture of the effects of KLS, GABA, and KLS-GABA co-crystal administration in the ethanol-gastric injury model, identifying processes not revealed by other studies by showing proteomic changes and related mechanisms in detail, particularly via modulation of the oxidative stress-related GSTP1 which suggests the higher gastric tolerability of KLS-GABA co-crystal in the analyzed model highlighting its clinical reliability.

## Linked entities

- **Proteins:** GSTP1 (glutathione S-transferase pi 1)
- **Chemicals:** ketoprofen (PubChem CID 3825), lysine (PubChem CID 866), gabapentin (PubChem CID 3446), ethanol (PubChem CID 702)

## Full-text entities

- **Genes:** MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, PDIA3 (protein disulfide isomerase family A member 3) [NCBI Gene 2923] {aka ER60, ERp57, ERp60, ERp61, GRP57, GRP58}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, VCL (vinculin) [NCBI Gene 7414] {aka CMD1W, CMH15, HEL114, MV, MVCL, VINC}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, HSP90AA1 (heat shock protein 90 alpha family class A member 1) [NCBI Gene 3320] {aka EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792] {aka EDAID2, IKBA, MAD-3, NFKBI}, CCK (cholecystokinin) [NCBI Gene 885], NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, MARVELD2 (MARVEL domain containing 2) [NCBI Gene 153562] {aka DFNB49, MARVD2, MRVLDC2, Tric}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, CAT (catalase) [NCBI Gene 847], GSTP1 (glutathione S-transferase pi 1) [NCBI Gene 2950] {aka DFN7, FAEES3, GST3, GSTP, GSTP1-1, HEL-S-22}, SLC2A4 (solute carrier family 2 member 4) [NCBI Gene 6517] {aka GLUT4}, CLDN5 (claudin 5) [NCBI Gene 7122] {aka AWAL, BEC1, CPETRL1, TMDVCF, TMVCF}, MUC5B (mucin 5B, oligomeric mucus/gel-forming) [NCBI Gene 727897] {aka MG1, MUC-5B, MUC5, MUC9}, CCT [NCBI Gene 907], CAPS (calcyphosine) [NCBI Gene 828] {aka CAPS1}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}
- **Diseases:** Chronic pain (MESH:D059350), gastric (MESH:D013272), inflammatory (MESH:D007249), cancer (MESH:D009369), H. pylori infection (MESH:D016481), inflammatory pain (MESH:D010146), Neuropathic pain (MESH:D009437), gastric cancer (MESH:D013274), neuroinflammatory (MESH:D000090862), gastric erosion (MESH:D014077), ORCID iD (MESH:C535742), epileptic (MESH:D004827), gastric ulceration (MESH:D013276)
- **Chemicals:** MOPS (MESH:C008550), acetic acid (MESH:D019342), polyacrylamide (MESH:C016679), water (MESH:D014867), Vitamin D (MESH:D014807), CO2 (MESH:D002245), CHAPS (MESH:C028213), ROS (MESH:D017382), SDS (MESH:D012967), lipid (MESH:D008055), urea (MESH:D014508), lysine (MESH:D008239), EDTA (MESH:D004492), ATP (MESH:D000255), calcium (MESH:D002118), IAA (MESH:D007460), KLS (MESH:C029946), methionine (MESH:D008715), HCL (MESH:D006851), MES (MESH:C004550), 4-HNE (-), glutamine (MESH:D005973), ETOH (MESH:D000431), glycerol (MESH:D005990), bromophenol blue (MESH:D001978), phosphatidylinositol (MESH:D010716), DTT (MESH:D004229), GABA (MESH:D000077206), thiourea (MESH:D013890), Ketoprofen (MESH:D007660)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** N87 — Homo sapiens (Human), Gastric tubular adenocarcinoma, Cancer cell line (CVCL_1603)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12306739/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12306739/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12306739/full.md

---
Source: https://tomesphere.com/paper/PMC12306739